Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Total Liabilities of $7.1 billion for Q1 2026, up 11.56% year-over-year from $6.4 billion in Q1 2025, and up 2.08% quarter-over-quarter from $7.0 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $7.1 billion for Q1 2026.
- In Q1 2026, Total Liabilities rose 11.56% year-over-year to $7.1 billion; the TTM figure through Mar 2026 stood at $7.1 billion (up 11.56% YoY), while the FY2025 annual figure was $7.0 billion, up 13.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $7.1 billion, up from $7.0 billion in the prior quarter.
- The five-year high for Total Liabilities was $7.5 billion in Q3 2025, with the low at $3.3 billion in Q1 2022.
- The 5-year median for Total Liabilities is $5.4 billion (2024), against an average of $5.5 billion.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities rose 6.84% in 2022, then jumped 41.79% in 2023.
- Vertex Pharmaceuticals' Total Liabilities stood at $4.2 billion in 2022, then rose by 21.51% to $5.1 billion in 2023, then gained by 18.91% to $6.1 billion in 2024, then gained by 13.94% to $7.0 billion in 2025, then grew by 2.08% to $7.1 billion in 2026.
- Business Quant data shows VRTX's Total Liabilities at $7.1 billion in Q1 2026, $7.0 billion in Q4 2025, and $7.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.18 Bn |
| Mar 31, 2026 | 7.12 Bn |
| Dec 31, 2025 | 6.98 Bn |
| Sep 30, 2025 | 7.54 Bn |
| Jun 30, 2025 | 6.86 Bn |
| Mar 31, 2025 | 6.38 Bn |
| Dec 31, 2024 | 6.12 Bn |
| Sep 30, 2024 | 6.61 Bn |
| Jun 30, 2024 | 5.36 Bn |
| Mar 31, 2024 | 5.37 Bn |
| Dec 31, 2023 | 5.15 Bn |
| Sep 30, 2023 | 5.21 Bn |
| Jun 30, 2023 | 4.88 Bn |
| Mar 31, 2023 | 4.54 Bn |
| Dec 31, 2022 | 4.24 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 3.65 Bn |
| Mar 31, 2022 | 3.35 Bn |
| Dec 31, 2021 | 3.33 Bn |
| Sep 30, 2021 | 3.09 Bn |